A Novel Ruthenium Antimicrobial Platform Technology - Preventing and Treating Multi-Drug Resistant Infections

新型钌抗菌平台技术——预防和治疗多重耐药感染

基本信息

批准号：
10050214
负责人：
金额：
$ 6.37万
依托单位：
METALLOBIO LIMITED
依托单位国家：
英国
项目类别：
Grant for R&D
财政年份：
2023
资助国家：
英国
起止时间：
2023 至无数据
项目状态：
未结题

来源：
https://gtr.ukri.org/projects?ref=10050214
关键词：
Novel Ruthenium Antimicrobial Platform Technology

项目摘要

MetalloBio is a University of Sheffield spin-out company co-founded by Dr Kirsty Smitten and Professor Jim Thomas. MetalloBio are developing a new series of antimicrobial compounds. The compounds are being developed as drugs to treat respiratory bacterial infections and as medical device coatings to prevent infections from developing at the medical device site.The compounds that underpin the platform are more active than current antibiotics, have a novel mechanism of action, little-to-no emergence of resistance and represent a new antimicrobial class. To put this into perspective a new antimicrobial class has not reached the clinic in over 30-years. The antimicrobial is in the preclinical stage of development and the coating technology prototype has been developed.This award accelerate MetalloBio's technology's development and reduce the time to the market, where maximum impact through improved patient quality of life and reduced death rates will be achieved. The project will allow MetalloBio to complete key preclinical experiments outlined by potential customers as essential, including a wide antimicrobial screen of 90 bacterial strains relevant to respiratory infections. Additionally, it will allow the team to scale the synthesis of the antimicrobials to a level that will allow incorporation into polymers for commercial applications. Finally, commercial validity will be studied with a top 10 medical device company, to determine if the polymer can be used to coat their medical device technology's.

Metallobio是Sheffield University的纺纱公司，由Kirsty Smitten博士和Jim Thomas教授共同创立。 Metallobio正在开发一系列新的抗菌化合物。这些化合物正在作为治疗呼吸细菌感染的药物开发，并作为医疗装置涂层，以防止在医疗设备部位开发感染。支撑该平台的化合物比当前的抗生素更为活跃，具有新颖的作用机理，几乎没有抗药性，耐药性却很少，并且代表了新的抗菌剂。从30年来的情况下，新的抗菌类别尚未到达诊所。抗菌剂处于开发的临床前阶段，并且已经开发了涂料技术原型。该奖项加速了Metallobio的技术的开发并减少了市场的时间，在这种情况下，通过改善患者生活质量和降低死亡率的最大影响。该项目将使Metallobio能够完成潜在客户概述的关键临床前实验，包括与呼吸道感染相关的90种细菌菌株的广泛抗菌筛查。此外，它将允许团队将抗微生物的合成扩展到将允许在商业应用中掺入聚合物的水平。最后，将向一家前十名医疗设备公司研究商业有效性，以确定聚合物是否可以用于涂上其医疗设备技术。